Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6639499 | 0.99 | PGR (0.53) | PGRBACE1PDE7AIP6K1IP6K3 | |
| SCHEMBL11641485 | 0.85 | PGR (0.71) | PGRPDE7AIP6K1IP6K3IP6K2 | |
| SCHEMBL5482190 | 0.83 | PGR (0.72) | PGRPDE7AIP6K1IP6K3IP6K2 | |
| SCHEMBL6637532 | 0.83 | BACE1 (0.52) | PGRBACE1HTR2APDE4APDE4B | |
| SCHEMBL4952486 | 0.82 | PGR (0.58) | PGRBACE1PDE7AIP6K1IP6K3 | |
| Hydrochloric Acid SCHEMBL6639312 | 0.82 | BACE1 (0.51) | PGRBACE1HTR2APDE4APDE4B | |
| SCHEMBL26666506 | 0.81 | PGR (0.69) | PGRPDE7AIP6K1IP6K3IP6K2 | |
| SCHEMBL29860221 | 0.81 | PGR (0.69) | PGRPDE7AIP6K1IP6K3IP6K2 | |
| Hydrochloric Acid SCHEMBL25355728 | 0.81 | PGR (0.57) | PGRBACE1PDE7AIP6K1IP6K3 | |
| SCHEMBL17596705 | 0.80 | BACE1 (0.49) | PGRBACE1HTR2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | claimed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | claimed |
| EP-1202994-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005790-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2001-01-25 | — | — | WO | claimed |
| US-6774132-B1 | Spirooxindole derivatives that act as analgesics | ASTRAZENECA AB (SE) | 2004-08-10 | — | — | US | disclosed |
| EP-1426375-A2 | Analgesic spiroindole derivatives | AstraZeneca AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1202994-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005790-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | OPRK1, OPRD1, OPRL1 | PGR 1652/4885BACE1 4822/4885PDE7A 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.